According to the Zhitong Finance App, Sansheng Pharmaceutical (01530.HK) announced its 2026 interim results. The group obtained revenue of 4.526 billion yuan, an increase of 3.91% over the previous year; profit attributable to the company's equity shareholders was 1,147 billion yuan, a decrease of 15.58% over the previous year; and the basic profit per share was 0.45 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.